Stephan Vagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7876215/publications.pdf

Version: 2024-02-01

62 5,519 papers citations

36 60 h-index g-index

68 68 docs citations

68 times ranked 9196 citing authors

#	Article	IF	Citations
1	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	27.8	702
2	Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Research, 2010, 38, 2757-2774.	14.5	322
3	elF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature, 2014, 513, 105-109.	27.8	287
4	Irresistible IRES. EMBO Reports, 2001, 2, 893-898.	4.5	247
5	Gâ€quadruplexes in RNA biology. Wiley Interdisciplinary Reviews RNA, 2012, 3, 495-507.	6.4	247
6	Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth. Cancer Research, 2009, 69, 8332-8340.	0.9	225
7	Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons. Biology of the Cell, 2003, 95, 169-178.	2.0	220
8	Alternative Translation of the Proto-oncogene c-mycby an Internal Ribosome Entry Site. Journal of Biological Chemistry, 1997, 272, 32061-32066.	3.4	219
9	Translational control of tumor immune escape via the elF4F–STAT1–PD-L1 axis in melanoma. Nature Medicine, 2018, 24, 1877-1886.	30.7	180
10	An interaction between U2AF 65 and CF Im links the splicing and 3′ end processing machineries. EMBO Journal, 2006, 25, 4854-4864.	7.8	179
11	Persistent Cancer Cells: The Deadly Survivors. Cell, 2020, 183, 860-874.	28.9	157
12	Essential role for the interaction between hnRNP H/F and a G quadruplex in maintaining p53 pre-mRNA 3′-end processing and function during DNA damage. Genes and Development, 2011, 25, 220-225.	5.9	155
13	A Single Internal Ribosome Entry Site Containing a G Quartet RNA Structure Drives Fibroblast Growth Factor 2 Gene Expression at Four Alternative Translation Initiation Codons. Journal of Biological Chemistry, 2003, 278, 39330-39336.	3.4	151
14	Heterogeneous Nuclear Ribonucleoprotein A1 Is a Novel Internal Ribosome Entry Site trans-Acting Factor That Modulates Alternative Initiation of Translation of the Fibroblast Growth Factor 2 mRNA. Journal of Biological Chemistry, 2005, 280, 4144-4153.	3.4	134
15	Cytoplasmic Relocalization of Heterogeneous Nuclear Ribonucleoprotein A1 Controls Translation Initiation of Specific mRNAs. Molecular Biology of the Cell, 2007, 18, 5048-5059.	2.1	128
16	Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i> . Clinical Cancer Research, 2012, 18, 263-272.	7.0	119
17	Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nature Structural and Molecular Biology, 2012, 19, 1139-1146.	8.2	117
18	Alternative Translation Initiation of the Moloney Murine Leukemia Virus mRNA Controlled by Internal Ribosome Entry Involving the p57/PTB Splicing Factor. Journal of Biological Chemistry, 1995, 270, 20376-20383.	3.4	108

#	Article	IF	Citations
19	DNA damage: RNA-binding proteins protect from near and far. Trends in Biochemical Sciences, 2014, 39, 141-149.	7. 5	103
20	The plasticity of mRNA translation during cancer progression and therapy resistance. Nature Reviews Cancer, 2021, 21, 558-577.	28.4	100
21	Subcellular Relocalization of a Trans-acting Factor Regulates XIAP IRES-dependent Translation. Molecular Biology of the Cell, 2007, 18, 1302-1311.	2.1	99
22	Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. Cancer Research, 2013, 73, 2247-2258.	0.9	86
23	IRESdb: the Internal Ribosome Entry Site database. Nucleic Acids Research, 2003, 31, 427-428.	14.5	79
24	Molecular Pathways: The elF4F Translation Initiation Complexâ€"New Opportunities for Cancer Treatment. Clinical Cancer Research, 2017, 23, 21-25.	7.0	75
25	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nature Communications, 2019, 10, 5713.	12.8	70
26	Position-dependent inhibition of the cleavage step of pre-mRNA 3′-end processing by U1 snRNP. Rna, 2000, 6, 178-188.	3.5	69
27	A physical and functional link between splicing factors promotes pre-mRNA 3′ end processing. Nucleic Acids Research, 2009, 37, 4672-4683.	14.5	68
28	Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis. Cancer Research, 2010, 70, 896-905.	0.9	59
29	A novel function for the U2AF 65 splicing factor in promoting preâ€mRNA 3′â€end processing. EMBO Reports, 2002, 3, 869-874.	4.5	57
30	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clinical Cancer Research, 2011, 17, 5562-5572.	7.0	56
31	Testosterone regulates FGFâ€2 expression during testis maturation by an IRESâ€dependent translational mechanism. FASEB Journal, 2006, 20, 476-478.	0.5	49
32	Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors. Cancer Research, 2011, 71, 4068-4073.	0.9	49
33	The G-Quadruplex-Specific RNA Helicase DHX36 Regulates p53 Pre-mRNA 3′-End Processing Following UV-Induced DNA Damage. Journal of Molecular Biology, 2017, 429, 3121-3131.	4.2	46
34	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization. Cancer Research, 2016, 76, 1476-1484.	0.9	44
35	Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut, 2010, 59, 934-942.	12.1	42
36	Characterization of a Short Isoform of Human Tgs1 Hypermethylase Associating with Small Nucleolar Ribonucleoprotein Core Proteins and Produced by Limited Proteolytic Processing. Journal of Biological Chemistry, 2008, 283, 2060-2069.	3.4	39

#	Article	IF	CITATIONS
37	DNA-Damage Response RNA-Binding Proteins (DDRBPs): Perspectives from a New Class of Proteins and Their RNA Targets. Journal of Molecular Biology, 2017, 429, 3139-3145.	4.2	36
38	Alternative splicing and breast cancer. RNA Biology, 2010, 7, 403-411.	3.1	35
39	Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. European Journal of Medicinal Chemistry, 2020, 203, 112653.	5.5	31
40	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Research, 2020, 48, 2676-2693.	14.5	30
41	hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget, 2016, 7, 16793-16805.	1.8	30
42	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis, 2014, 35, 807-815.	2.8	29
43	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research, 2014, 74, 2238-2245.	0.9	28
44	The c.5242C> A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Research and Treatment, 2010, 120, 391-399.	2.5	23
45	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. Cell Cycle, 2016, 15, 295-302.	2.6	23
46	Post-transcriptional control of gene expression through subcellular relocalization of mRNA binding proteins. Biochemical Pharmacology, 2008, 76, 1395-1403.	4.4	21
47	Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection. Journal of Virology, 2013, 87, 6668-6677.	3.4	21
48	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. Cell Cycle, 2018, 17, 605-615.	2.6	21
49	Nucleotide Variability and Translation Efficiency of the 5′ Untranslated Region of Hepatitis A Virus: Update from Clinical Isolates Associated with Mild and Severe Hepatitis. Journal of Virology, 2010, 84, 10139-10147.	3.4	18
50	Pharmacologicalâ€based translational induction of transgene expression in mammalian cells. EMBO Reports, 2004, 5, 721-727.	4.5	15
51	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	7.0	12
52	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Cell Cycle, 2016, 15, 2405-2409.	2.6	11
53	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. European Journal of Dermatology, 2014, 24, 265-267.	0.6	10
54	Decreased efficiency of <i>MSH6</i> mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families. Cell Cycle, 2012, 11, 2578-2580.	2.6	8

#	Article	IF	CITATIONS
55	Reciprocal Links between Pre-messenger RNA 3′-End Processing and Genome Stability. Trends in Biochemical Sciences, 2021, 46, 579-594.	7.5	8
56	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 518-525.	7.0	7
57	Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. Cell, 2018, 175, 901-902.	28.9	5
58	Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition. Cancers, 2022, 14, 1177.	3.7	5
59	Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells. Cancers, 2022, 14, 2113.	3.7	3
60	In situ detection of the eIF4F translation initiation complex in mammalian cells and tissues. STAR Protocols, 2021, 2, 100621.	1.2	1
61	Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents. Open Medicinal Chemistry Journal, 2018, 12, 74-83.	2.4	0
62	At the crossroads of RNA biology, genome integrity and cancer. Bulletin Du Cancer, 2022, , .	1.6	0